Ferrer Internacional

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Loxapine (Adasuve)No recent activity
Phase 3
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
CNIC-Ferrer polypill(Trinomia)No recent activity
Phase 2
Multi-mechanism secondary-prevention polypillSmall molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 August 2022Topline resultCNIC-Ferrer polypillPhase 3 SECURE (NCT02596126) met its primary endpoint: polypill reduced major cardiovascular events versus usual care

Financial reports

No financial reports recorded.